Skip to main content
PMC home page
Virologica Sinica logoLink to Virologica Sinica
. 2016 Mar 17;31(2):110–117. doi: 10.1007/s12250-015-3691-3

Recent advances in synthetic carbohydrate-based human immunodeficiency virus vaccines

Zhenyuan Wang 1, Chunjun Qin 1, Jing Hu 1,2, Xiaoqiang Guo 1, Jian Yin 1,✉
PMCID: PMC8193421  PMID: 26992403

Abstract

An effective vaccine for human immunodeficiency virus (HIV) is urgently needed to prevent HIV infection and progression to acquired immune deficiency syndrome (AIDS). As glycosylation of viral proteins becomes better understood, carbohydrate-based antiviral vaccines against special viruses have attracted much attention. Significant efforts in carbohydrate synthesis and immunogenicity research have resulted in the development of multiple carbohydrate-based HIV vaccines. This review summarizes recent advances in synthetic carbohydrate-based vaccines design strategies and the applications of these vaccines in the prevention of HIV.

graphic file with name 12250_2015_3691_Fig1_HTML.jpg

Keywords: vaccine, human immunodeficiency virus (HIV), glycoprotein, N-glycosylation, neutralizing antibodies

Footnotes

ORCID: 0000-0002-2284-1666

References

  1. Adams EW, Ratner DM, Bokesch HR, McMahon JB, O'Keefe BR, Seeberger PH. Oligosaccharide and glycoprotein microarrays as tools in HIV glycobiology; glycan-dependent gp120/protein interactions. Chem Biol. 2004;11:875–881. doi: 10.1016/j.chembiol.2004.04.010. [DOI] [PubMed] [Google Scholar]
  2. Alama SM, Dennisona SM, Aussedatd B, Vohrad Y, Parkd PK, Fernández-Tejadad A, Stewarta S, Jaegera FH, Anastia K, Blinna JH, Keplere TB, Bonsignori M, Liao H-X, Sodroski JG, Danishefsky SJ, Haynesa BF. Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proc Natl Acad Sci U S A. 2013;110:18214–18219. doi: 10.1073/pnas.1317855110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Anish C, Schumann B, Pereira CL, Seeberger PH. Chemical biology approaches to designing defined carbohydrate vaccines. Chem Biol. 2014;21:38–50. doi: 10.1016/j.chembiol.2014.01.002. [DOI] [PubMed] [Google Scholar]
  4. Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov. 2010;9:308–324. doi: 10.1038/nrd3012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Astronomo RD, Kaltgrad E, Udit AK, Wang SK, Doores KJ, Huang CY, Pantophlet R, Paulson JC, Wong CH, Finn MG, Burton DR. Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. Chem Biol. 2010;17:357–370. doi: 10.1016/j.chembiol.2010.03.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Astronomo RD, Lee HK, Scanlan CN, Pantophlet R, Huang CY, Wilson IA, Blixt O, Dwek RA, Wong CH, Burton DR. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120. J Virol. 2008;82:6359–6368. doi: 10.1128/JVI.00293-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Blattner C, Lee JH, Sliepen K, Derking R, Falkowska E P A, Cupo A, Julien J-P G M, Lee PS, Peng W, Paulson JC, Poignard P, Burton DR, Moore JP, Sanders RW, Wilson IA, Ward AB. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014;40:669–680. doi: 10.1016/j.immuni.2014.04.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol. 2015;16:571–576. doi: 10.1038/ni.3158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cai H, Huang ZH, Shi L, Sun ZY, Zhao YF, Kunz H, Li YM. Variation of the glycosylation pattern in MUC1 glycopeptide BSA vaccines and its influence on the immune response. Angew Chem Int Ed Engl. 2012;51:1719–1723. doi: 10.1002/anie.201106396. [DOI] [PubMed] [Google Scholar]
  10. Calarese DA, Lee HK, Huang CY, Best MD, Astronomo RD, Stanfield RL, Katinger H, Burton DR, Wong CH, Wilson IA. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A. 2005;102:13372–13377. doi: 10.1073/pnas.0505763102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 2003;300:2065–2071. doi: 10.1126/science.1083182. [DOI] [PubMed] [Google Scholar]
  12. Calin O, Eller S, Seeberger PH. Automated polysaccharide synthesis: assembly of a 30mer mannoside. Angew Chem Int Ed Engl. 2013;52:5862–5865. doi: 10.1002/anie.201210176. [DOI] [PubMed] [Google Scholar]
  13. Cavallari M, Stallforth P, Kalinichenko A, Rathwell DCK, Gronewold TMA, Adibekian A, Mori L, Landmann R, Seeberger PH, Libero GD. A semisynthetic carbohydrate-lipid vaccine that protects against S. pneumoniae in mice. Nat Chem Biol. 2014;10:950–958. doi: 10.1038/nchembio.1650. [DOI] [PubMed] [Google Scholar]
  14. Ciobanu M, Huang KT, Daguer JP, Barluenga S, Chaloin O, Schaeffer E, Mueller CG, Mitchell DA, Winssinger N. Selection of a synthetic glycan oligomer from a library of DNAtemplated fragments against DC-SIGN and inhibition of HIV gp120 binding to dendritic cells. Chem Commun (Camb) 2011;47:9321–9323. doi: 10.1039/c1cc13213j. [DOI] [PubMed] [Google Scholar]
  15. Crispin M, Doores KJ. Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Curr Opin Virol. 2015;11:63–69. doi: 10.1016/j.coviro.2015.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Danishefsky SJ, Shue YK, Chang MN, Wong CH. Development of Globo-H cancer vaccine. Acc Chem Res. 2015;48:643–652. doi: 10.1021/ar5004187. [DOI] [PubMed] [Google Scholar]
  17. de Goede AL, Vulto AG, Osterhaus AD, Gruters RA. Understanding HIV infection for the design of a therapeutic vaccine. Part II: Vaccination strategies for HIV. Ann Pharm Fr. 2015;73:169–179. doi: 10.1016/j.pharma.2014.11.003. [DOI] [PubMed] [Google Scholar]
  18. Deng S, Bai L, Reboulet R, Matthew R, Engler DA, Teyton L, Bendelac A, Savage PB. A peptide-free, liposome-based oligosaccharide vaccine, adjuvanted with a natural killer T cell antigen, generates robust antibody responses. Chem Sci. 2014;5:1437–1441. doi: 10.1039/C3SC53471E. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Doores KJ, Fulton Z, Hong V, Patel MK, Scanlan CN, Wormald MR, Finn MG, Burton DR, Wilson IA, Davis BG. A nonself sugar mimic of the HIV glycan shield shows enhanced antigenicity. Proc Natl Acad Sci U S A. 2010;107:17107–17112. doi: 10.1073/pnas.1002717107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Eller S, Collot M, Yin J, Hahm HS, Seeberger PH. Automated solid-phase synthesis of chondroitin sulfate glycosaminoglycans. Angew Chem Int Ed Engl. 2013;52:5858–5861. doi: 10.1002/anie.201210132. [DOI] [PubMed] [Google Scholar]
  21. Ensoli B, Cafaro A, Monini P, Marcotullio S, Ensoli F. Challenges in HIV Vaccine Research for Treatment and Prevention. Front Immunol. 2014;5:417. doi: 10.3389/fimmu.2014.00417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Fernandez-Tejada A, Canada FJ, Jimenez-Barbero J. Recent Developments in Synthetic Carbohydrate-Based Diagnostics, Vaccines, and Therapeutics. Chemistry. 2015;21:10616–10628. doi: 10.1002/chem.201500831. [DOI] [PubMed] [Google Scholar]
  23. Fernandez-Tejada A, Haynes BF, Danishefsky SJ. Designing synthetic vaccines for HIV. Expert Rev Vaccines. 2015;14:815–831. doi: 10.1586/14760584.2015.1027690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Gorska K, Huang KT, Chaloin O, Winssinger N. DNA-tem-plated homo-and heterodimerization of peptide nucleic acid encoded oligosaccharides that mimick the carbohydrate epitope of HIV. Angew Chem Int Ed Engl. 2009;48:7695–7700. doi: 10.1002/anie.200903328. [DOI] [PubMed] [Google Scholar]
  25. Haji-Ghassemi O, Blackler R M, Young N, Evans SV. Antibody recognition of carbohydrate epitopes. Glycobiology. 2015;25:920–952. doi: 10.1093/glycob/cwv037. [DOI] [PubMed] [Google Scholar]
  26. Haynes BF. New approaches to HIV vaccine development. Curr Opin Immunol. 2015;35:39–47. doi: 10.1016/j.coi.2015.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hecht ML, Stallforth P, Silva DV, Adibekian A, Seeberger PH. Recent advances in carbohydrate-based vaccines. Curr Opin Chem Biol. 2009;13:354–359. doi: 10.1016/j.cbpa.2009.05.127. [DOI] [PubMed] [Google Scholar]
  28. Horiya S, Bailey JK, Temme J G, Schlippe YV, Krauss IJ. Directed evolution of multivalent glycopeptides tightly recognized by HIV antibody 2G12. J Am Chem Soc. 2014;136:5407–5415. doi: 10.1021/ja500678v. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Horiya S, MacPherson IS, Krauss IJ. Recent strategies targeting HIV glycans in vaccine design. Nat Chem Biol. 2014;10:990–999. doi: 10.1038/nchembio.1685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hsu CH, Hung SC, Wu CY, Wong CH. Toward automated oligosaccharide synthesis. Angew Chem Int Ed Engl. 2011;50:11872–11923. doi: 10.1002/anie.201100125. [DOI] [PubMed] [Google Scholar]
  31. Hu J, Qiu L, Wang X, Zou X, Lu M, Yin J. Carbohydratebased vaccine adjuvants -discovery and development. Expert Opin Drug Discov. 2015;10:1133–1144. doi: 10.1517/17460441.2015.1067198. [DOI] [PubMed] [Google Scholar]
  32. Hurevich M, Seeberger PH. Automated glycopeptide assembly by combined solid-phase peptide and oligosaccharide synthesis. Chem Commun (Camb) 2014;50:1851–1853. doi: 10.1039/c3cc48761j. [DOI] [PubMed] [Google Scholar]
  33. Ingale S, Wolfert MA, Gaekwad J, Buskas T, Boons GJ. Robust immune responses elicited by a fully synthetic threecomponent vaccine. Nat Chem Biol. 2007;3:663–667. doi: 10.1038/nchembio.2007.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Joyce JG, Krauss IJ, Song HC, Opalka DW, Grimm KM, Nahas DD, Esser MT, Hrin R, Feng M, Dudkin VY, Chastain M, Shiver JW, Danishefsky SJ. An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions. Proc Natl Acad Sci U S A. 2008;105:15684–15689. doi: 10.1073/pnas.0807837105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, Ramos A, Diwanji DC, Pejchal R, Cupo A, Katpally U, Depetris RS, Stanfield RL, McBride R, Marozsan AJ, Paulson JC, Sanders RW, Moore JP, Burton DR, Poignard P, Ward AB, Wilson IA. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 2013;9:e1003342. doi: 10.1371/journal.ppat.1003342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Kabanova A, Adamo R, Proietti D, Berti F, Tontini M, Rappuoli R, Costantino P. Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates. Glycoconj J. 2010;27:501–513. doi: 10.1007/s10719-010-9295-0. [DOI] [PubMed] [Google Scholar]
  37. Kandasamy J, Hurevich M, Seeberger PH. Automated solid phase synthesis of oligoarabinofuranosides. Chem Commun (Camb) 2013;49:4453–4455. doi: 10.1039/c3cc00042g. [DOI] [PubMed] [Google Scholar]
  38. Kandasamy J, Schuhmacher F, Hahm HS, Klein JC, Seeberger PH. Modular automated solid phase synthesis of dermatan sulfate oligosaccharides. Chem Commun (Camb) 2014;50:1875–1877. doi: 10.1039/c3cc48860h. [DOI] [PubMed] [Google Scholar]
  39. Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol. 2013;20:796–803. doi: 10.1038/nsmb.2594. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Krauss IJ, Joyce JG, Finnefrock AC, Song HC, Dudkin VY, Geng X, Warren JD, Chastain M, Shiver JW, Danishefsky SJ. Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody. J Am Chem Soc. 2007;129:11042–11044. doi: 10.1021/ja074804r. [DOI] [PubMed] [Google Scholar]
  41. Kröck L, Esposito D, Castagner B, Wang C-C, Bindschädler P, Seeberger PH. Streamlined access to conjugation-ready glycans by automated synthesis. Chem Sci. 2012;3:1617–1622. [Google Scholar]
  42. Li H, Li B, Song H, Breydo L, Baskakov IV, Wang LX. Chemoenzymatic synthesis of HIV-1 V3 glycopeptides carrying two N-glycans and effects of glycosylation on the peptide domain. J Org Chem. 2005;70:9990–9996. doi: 10.1021/jo051729z. [DOI] [PubMed] [Google Scholar]
  43. Li H, Wang L-X. Design and synthesis of a template-assembled oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12. Org Biomol Chem. 2004;2:483–488. doi: 10.1039/b314565d. [DOI] [PubMed] [Google Scholar]
  44. Liu H, Bi W, Wang Q, Lu L, Jiang S. Receptor binding domain based HIV vaccines. Biomed Res Int. 2015;2015:594109–594117. doi: 10.1155/2015/594109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. MacPherson IS, Temme JS, Habeshian S, Felczak K, Pankiewicz K, Hedstrom L, Krauss IJ. Multivalent glycocluster design through directed evolution. Angew Chem Int Ed Engl. 2011;50:11238–11242. doi: 10.1002/anie.201105555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Mann JK, Ndung'u T. HIV-1 vaccine immunogen design strategies. Virol J. 2015;12:3–13. doi: 10.1186/s12985-014-0221-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Marradi M D, Gianvincenzo P, Enriquez-Navas PM, Martinez-Avila OM, Chiodo F, Yuste E, Angulo J, Penades S. Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12. J Mol Biol. 2011;410:798–810. doi: 10.1016/j.jmb.2011.03.042. [DOI] [PubMed] [Google Scholar]
  48. Mayr LM, Zolla-Pazner S. 2015. Antibodies Targeting the Envelope of HIV-1. Microbiol Spectr, 3: AID-0025-2014. [DOI] [PubMed]
  49. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, Shahzad-ul-Hussan S, Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature. 2011;480:336–343. doi: 10.1038/nature10696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Minor PD. Live attenuated vaccines: Historical successes and current challenges. Virology. 2015;479–480:379–392. doi: 10.1016/j.virol.2015.03.032. [DOI] [PubMed] [Google Scholar]
  51. Morelli L, Poletti L, Lay L. Carbohydrates and Immunology: Synthetic Oligosaccharide Antigens for Vaccine Formulation. Eur J Org Chem. 2011;2011:5723–5777. [Google Scholar]
  52. Moulard M, Decroly E. Biochimica et Biophysica Acta. 2000. Maturation of HIV envelope glycoprotein precursors by cellular endoproteases; pp. 121–132. [DOI] [PubMed] [Google Scholar]
  53. Ni J, Song H, Wang Y, Stamatos NM, Wang LX. Toward a carbohydrate-based HIV-1 vaccine: synthesis and immunological studies of oligomannose-containing glycoconjugates. Bioconjug Chem. 2006;17:493–500. doi: 10.1021/bc0502816. [DOI] [PubMed] [Google Scholar]
  54. Nikolaev AV, Sizova OV. Synthetic neoglycoconjugates of cell-surface phosphoglycans of Leishmania as potential antiparasite carbohydrate vaccines. Biochemistry(Mosc) 2011;76:761–773. doi: 10.1134/S0006297911070066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Pancera M, Shahzad-Ul-Hussan S, Doria-Rose NA, McLellan JS, Bailer RT, Dai K, Loesgen S, Louder MK, Staupe RP, Yang Y, Zhang B, Parks R, Eudailey J, Lloyd KE, Blinn J, Alam SM, Haynes BF, Amin MN, Wang LX, Burton DR, Koff WC, Nabel GJ, Mascola JR, Bewley CA, Kwong PD. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol. 2013;20:804–813. doi: 10.1038/nsmb.2600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, Stanfield RL, Julien JP, Ramos A, Crispin M, Depetris R, Katpally U, Marozsan A, Cupo A, Maloveste S, Liu Y, McBride R, Ito Y, Sanders RW, Ogohara C, Paulson JC, Feizi T, Scanlan CN, Wong CH, Moore JP, Olson WC, Ward AB, Poignard P, Schief WR, Burton DR, Wilson IA. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 2011;334:1097–1103. doi: 10.1126/science.1213256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Peri F. Clustered carbohydrates in synthetic vaccines. Chem Soc Rev. 2013;42:4543–4556. doi: 10.1039/c2cs35422e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Plante OJ, Palmacci ER, Seeberger PH. Automated solidphase synthesis of oligosaccharides. Science. 2001;291:1523–1527. doi: 10.1126/science.1057324. [DOI] [PubMed] [Google Scholar]
  59. Qin Q, Yin Z, Bentley P, Huang X. Carbohydrate antigen delivery by water soluble copolymers as potential anti-cancer vaccines. Med Chem Commun. 2014;5:1126–1129. doi: 10.1039/C4MD00103F. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Rodrigues AF, Soares HR, Guerreiro MR, Alves PM, Coroadinha AS. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology. Biotechnol J. 2015;10:1329–1344. doi: 10.1002/biot.201400387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Roy R C, Shiao T. Organic Chemistry and Immunochemical Strategies in the Design of Potent Carbohydrate-based Vaccines. CHIMIA. 2011;65:24–29. doi: 10.2533/chimia.2011.24. [DOI] [PubMed] [Google Scholar]
  62. Safari D, Marradi M, Chiodo F T, Dekker HA, Shan Y, Adamo R, Oscarson S, Rijkers GT, Lahmann M, Kamerling JP, Penades S, Snippe H. Gold nanoparticles as carriers for a synthetic Streptococcus pneumoniae type 14 conjugate vaccine. Nanomedicine (Lond) 2012;7:651–662. doi: 10.2217/nnm.11.151. [DOI] [PubMed] [Google Scholar]
  63. Said Hassane F, Phalipon A, Tanguy M, Guerreiro C, Belot F, Frisch B, Mulard LA, Schuber F. Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen. Vaccine. 2009;27:5419–5426. doi: 10.1016/j.vaccine.2009.06.031. [DOI] [PubMed] [Google Scholar]
  64. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP. The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120. J Virol. 2002;76:7293–7305. doi: 10.1128/JVI.76.14.7293-7305.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Scanlan CN, Pantophlet R, Wormald M O, Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of 12 Mannose Residues on the Outer Face of gp120. J Virol. 2002;76:7306–7321. doi: 10.1128/JVI.76.14.7306-7321.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Schmidt D, Schuhmacher F, Geissner A, Seeberger PH, Pfrengle F. Automated synthesis of arabinoxylan-oligosaccharides enables characterization of antibodies that recognize plant cell wall glycans. Chemistry. 2015;21:5709–5713. doi: 10.1002/chem.201500065. [DOI] [PubMed] [Google Scholar]
  67. Seeberger PH. The logic of automated glycan assembly. Acc Chem Res. 2015;48:1450–1463. doi: 10.1021/ar5004362. [DOI] [PubMed] [Google Scholar]
  68. Seeberger PH, Werz DB. Automated synthesis of oligosaccharides as a basis for drug discovery. Nat Rev Drug Discov. 2005;4:751–763. doi: 10.1038/nrd1823. [DOI] [PubMed] [Google Scholar]
  69. Swarts BM, Guo Z. Carbohydrate-Based Vaccines and Immunotherapies. Hoboken: Wiley; 2009. pp. 167–193. [Google Scholar]
  70. Temme JS, Drzyzga MG, MacPherson IS, Krauss IJ. Directed evolution of 2G12-targeted nonamannose glycoclusters by SELMA. Chemistry. 2013;19:17291–17295. doi: 10.1002/chem.201303848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Temme JS, MacPherson IS, DeCourcey JF, Krauss IJ. High temperature SELMA: evolution of DNA-supported oligomannose clusters which are tightly recognized by HIV bnAb 2G12. J Am Chem Soc. 2014;136:1726–1729. doi: 10.1021/ja411212q. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Thompson P, Lakshminarayanan V, Supekar NT, Bradley JM, Cohen PA, Wolfert MA, Gendler SJ, Boons G-J. Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide. Chem Commun (Camb) 2015;51:10214–10217. doi: 10.1039/c5cc02199e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Tongo M, Burgers WA. Challenges in the design of a T cell vaccine in the context of HIV-1 diversity. Viruses. 2014;6:3968–3990. doi: 10.3390/v6103968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. UNAIDS. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2015. [Google Scholar]
  75. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, Mitcham JL, Hammond PW, Olsen OA, Phung P, Fling S, Wong CH, Phogat S, Wrin T, Simek MD, Protocol GPI, Koff WC, Wilson IA, Burton DR, Poignard P. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477:466–470. doi: 10.1038/nature10373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Protocol GPI, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326:285–289. doi: 10.1126/science.1178746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Wang J, Li H, Zou G, Wang LX. Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study. Org Biomol Chem. 2007;5:1529–1540. doi: 10.1039/b702961f. [DOI] [PubMed] [Google Scholar]
  78. Wang LX. Toward oligosaccharide-and glycopeptide-based HIV vaccines. Curr Opin Drug Disc. 2006;9:194–206. [PubMed] [Google Scholar]
  79. Wang LX, Ni J, Singh S, Li H. Binding of high-mannosetype oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design. Chem Biol. 2004;11:127–134. doi: 10.1016/j.chembiol.2003.12.020. [DOI] [PubMed] [Google Scholar]
  80. Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, Wong CH. Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc Natl Acad Sci U S A. 2008;105:3690–3695. doi: 10.1073/pnas.0712326105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Yang Q, Li C, Wei Y, Huang W, Wang LX. Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc. Bioconjug Chem. 2010;21:875–883. doi: 10.1021/bc9004238. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Virologica Sinica are provided here courtesy of Wuhan Institute of Virology, Chinese Academy of Sciences

RESOURCES